activin

(redirected from Activin A)
Also found in: Dictionary.

ac·tiv·in

(ak'ti-vin),
Placental hormone that reaches maximum levels in maternal serum during labor; helps to regulate production of gonadotropin-releasing hormones, human chorionic gonadotropin, and steroids by the placenta.
[active + -in]

activin

/ac·ti·vin/ (ak´tĭ-vin) a nonsteroidal regulator synthesized in the pituitary glands and gonads that stimulates the secretion of follicle-stimulating hormone.

activin

(ăk′tə-vĭn, ăk-tĭv′ĭn)
n.
A polypeptide growth factor that is synthesized in the pituitary gland and the gonads and stimulates the secretion of follicle-stimulating hormone.

Activin

Either of two dimeric proteins belonging to the TGF-beta superfamily (as do inhibin and bone morphogenic protein) which act primarily through SMADs, a class of signal transducers, which are involved in DNA-binding and signal transduction. Activins are involved in all stages of the cell cycle: proliferation, differentiation, metabolism, homeostasis, and death (apoptosis), as well as immune response and tissue repair—activins A and B are highly expressed during wound repair and healing, and have yin-yang relationship with inhibin. Activins are involved in differentiation of erythroid precursors and erythroleukemia cell lines, neuronal survival, stimulation of insulin and anterior pituitary hormone secretion, regulation of the menstrual cycle, increasing FSH production and granulosa cell differentiation by binding to follistatin, an FSH release inhibitor.

ac·tiv·in

(ak'ti-vin)
Placental hormone that reaches maximum levels in maternal serum during labor.

activin

a gonadal peptide hormone isolated from follicular fluid; has an unidentified role in stimulating FSH secretion.
References in periodicals archive ?
The researchers created a soluble version of the activin A receptor - which is thought to affect both myostatin and activin A signalling - by fusing a piece of human activin receptor to an antibody.
Elevated pretreatment serum activin A levels were correlated with reduced progression free survival and overall survival and patients with persistently high activin A levels had significantly worsened outcomes compared to those with low activin A levels.
Acceleron and Celgene are collaborating to discover and develop products that target activin A.
Heparinized samples of blood taken at 4 time points [before surgery (time 0), during surgery before CPB (time 1), at the end of CPB (time 2), at the end of surgery (time 3), and 12 h after surgery (time 4)] were assayed for activin A.
Activin A was measured by means of a specific 2-site enzyme immunoassay (Serotec) (11).
Activin A was measured at first urination (time 0, mean collection time 1 h), 12 (time 1), 24 (time 2), 48 (time 3), and 72 (time 4) h of age.
Cutoff points for defining high activin A for prediction of HIE were chosen by ROC analysis (13).
Activin A measurements were performed blinded and in duplicate with a specific 2-site enzyme immunoassay from Serotec (12).
We used the Kolmogorov-Smirnov test to confirm that the distributions of activin A, Hyp, and Xan concentrations and NRBC counts were not gaussian.
On admission, all patients were checked against routine clinical and laboratory values, and CSF samples were obtained by lumbar puncture for routine examination and activin A assessment in the first 24-h after birth.
CSF samples (150 /,L) were centrifuged at 900g for 10 min, and supernatants were stored at -70 [degrees]C before measurement of activin A by ELISA (Serotec), which was performed in duplicate, as described previously (21), without knowledge of the clinical classification.
Characterization and determination of the biological activities of noncleavable high molecular weight forms of inhibin A and activin A.

Full browser ?